MarginsXMarginsX
Home › Markets › Health Care › PTGX

Protagonist Therapeutics Inc. (PTGX)

PTGX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$124.83
-4.67% on the day
Market cap
$8.1B
Mid cap
Revenue · 2025
$46.0M
-89.4% on 2024
Net income · 2025
-$130.1M
-282.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1377121/000110465926019696/0001104659-26-019696-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPTGX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2016
SEC CIK0001377121
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$46.0M
Net income-$130.1M
Operating income-$158.1M
Net margin-282.8%
Operating margin-343.6%
Revenue growth-89.4%
Cash$128.4M
Total assets$668.2M
P/E (computed)Net income was not positive
P/S (computed)177.1×

Warning signs

Cash runway
Cash-flow positive
$498.3M cash at September 30, 2026
Share count, 1 year
+4.4%
2025-10-29 to 2026-10-31 · +13.2% over 3 years
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
-$80.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-06
Cash and burn$498.3M cash; operating cash flow $27.5M a quarter.Report 2026-09-30
Shares outstanding65,270,114 (2026-10-31); 62,515,666 a year earlier; 57,678,122 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-03-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $80.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$274.4M$220.0M-$23.2M$498.3MNo debt tags$551.7M10-Q 2026-11-06
Q2 2026
2026-06-30
$213.5M$162.8M$219.1M$420.1MNo debt tags$282.0M10-Q 2026-08-05
Q1 2026
2026-03-31
$56.4M$3.8M-$48.9M$193.7MNo debt tags$74.1M10-Q 2026-05-05
Q4 2025
2025-12-31
$7.4M-$44.4M-$37.0M$128.4MNo debt tags$46.0M10-K 2026-02-25
Q3 2025
2025-09-30
$4.7M-$39.3M-$1.9M$113.7MNo debt tags$209.2M10-Q 2026-11-06
Q2 2025
2025-06-30
$5.5M-$34.8M-$28.8M$168.5MNo debt tags$209.2M10-Q 2026-08-05
Q1 2025
2025-03-31
$28.3M-$11.7M$125.4M$139.7MNo debt tags$207.8M10-Q 2026-05-05
Q4 2024
2024-12-31
$170.6M$131.7M-$29.2M$97.2MNo debt tags$434.4M10-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2025-08-06
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-11-06
Latest current report
FORM 8-K
8-K2026-11-05
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 707 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.8%
1 month-5.4%
3 months-13.5%
Year to date+49.9%
1 year+57.3%
From 52-week high-17.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ALKSAlkermes plc$46.53-1.06%$7.8B
PRAXPraxis Precision Medicines Inc.$310.27-5.44%$8.7B
CORTCorcept Therapeutics Incorporated$69.22-5.10%$7.6B
RYTMRhythm Pharmaceuticals Inc.$107.48-6.56%$7.5B
CYTKCytokinetics Incorporated$53.17-5.27%$7.4B
KNSAKiniksa Pharmaceuticals International plc$94.23-2.18%$7.4B
AMRXAmneal Pharmaceuticals Inc.$21.23-0.70%$7.4B
ABVXAbivax SA$83.61-4.53%$7.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier